कृपया अन्य खोज का प्रयास करें
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Norio Aikawa | 74 | 2004 | Head of Drug Discovery & Support Business, Head of IP & Legal Department and Director |
Kohichiro Yoshino | 73 | 2003 | CEO, President & Representative Director |
Tsuguo Ogasawara | 84 | 2005 | Independent Outside Director |
Teruo Takayanagi | 77 | 2015 | Independent Outside Director |
Atsuo Arita | 80 | 2004 | Independent Outside Director |
Takao Matsui | - | 2019 | Independent Outside Director |
Emi Yamamoto | 53 | 2015 | GM of Business Mgt., Accounting, HR, General Affairs, CFO, Director & President - CarnaBio USA |
Masaaki Sawa | 53 | 2015 | GM of Research & Development Division, Chief Scientific Officer and Director |
Akinori Arimura | 60 | 2019 | GM of Clinical Development, R&D, Chief Development Officer of CarnaBio USA & Director |
Kaoru Suzuki | - | 2024 | Independent Outside Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है